(.pdf) dr.ssa Antonella Ferro - Progettoeventi
(.pdf) dr.ssa Antonella Ferro - Progettoeventi (.pdf) dr.ssa Antonella Ferro - Progettoeventi
Malattia Metastatica
Trastuzumab has transformed the prognosis of HER2+ breast cancer Overall survival probability 1.0 0.8 0.6 0.4 0.2 0 0 12 24 36 48 60 Months from diagnosis HER2+/trastuzumab HER2 – HER2+/no trastuzumab Dawood, et al. ASCO 2008 (abstract 1018)
- Page 1 and 2: Utilizzo dei farmaci nei diversi co
- Page 3 and 4: HER2 positive breast cancer “Targ
- Page 5 and 6: Trastuzumab (Herceptin) • Il Tras
- Page 7 and 8: Trastuzumab binds to ErbB2 on tumou
- Page 9 and 10: Antibody-Dependent Cellular Cytotox
- Page 11 and 12: Potenziale meccanismo di trastuzuma
- Page 13: Malattia adiuvante
- Page 17 and 18: DFS: Sequential (Arm B: AC → T
- Page 19 and 20: Malattia Neo- adiuvante
- Page 21: Studio NOAH: Event Free Survival ne
- Page 25 and 26: Definition of resistance In most tu
- Page 27 and 28: Truncated HER2 (p95 HER2 ): clinica
- Page 29 and 30: Trastuzumab Capecitabine von Minckw
- Page 31 and 32: GBG 26/BIG 03-05: main results Cape
- Page 33 and 34: Phase III, randomised, controlled s
- Page 35 and 36: Lapatinib • Binds to intracellula
- Page 37 and 38: Lapatinib may sensitise HER2 positi
- Page 39 and 40: Pertuzumab • Pertuzumab, inibitor
- Page 41 and 42: HER2 dimerization is key to signali
- Page 43 and 44: Trastuzumab binds to subdomain IV o
- Page 45 and 46: Trastuzumab and pertuzumab may have
- Page 47 and 48: Receptor-T-DM1 complex is internali
Trastuzumab has transformed the<br />
prognosis of HER2+ breast cancer<br />
Overall survival probability<br />
1.0<br />
0.8<br />
0.6<br />
0.4<br />
0.2<br />
0<br />
0 12 24 36 48 60<br />
Months from diagnosis<br />
HER2+/trastuzumab<br />
HER2 –<br />
HER2+/no trastuzumab<br />
Dawood, et al. ASCO 2008 (abstract 1018)
Change language